stockrowRadNet, Inc.
RDNT Healthcare Diagnostics & Research
RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024.
- Revenue
- +25.0%
- EPS
- −47.4%
- Free cash flow
- −43.2%
- Total debt
- +21.2%
Quarter to June 2026, against a year earlier
Follow RDNT
Alert me
RadNet, Inc. (RDNT) Return on assets
RadNet, Inc.'s return on assets over the twelve months to 30 June 2026 was −0.55%, down 0.0 percentage points from fiscal 2025 (−0.53%). Over the past ten years it has ranged from −0.86% (fiscal 2020) to 3.26% (fiscal 2018); the current reading is higher than 18% of that period. That is above the Diagnostics & Research industry median of −6.05% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −0.53% | (0.62) |
| FY2024 | 0.09% | (0.03) |
| FY2023 | 0.12% | (0.35) |
| FY2022 | 0.47% | (0.82) |
| FY2021 | 1.29% | 2.15 |
| FY2020 | −0.86% | (1.93) |
| FY2019 | 1.07% | (2.19) |
| FY2018 | 3.26% | 3.25 |
| FY2017 | 0.01% | (0.85) |
| FY2016 | 0.86% | (0.12) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| CDNA CareDx, Inc. compare | 24.0% |
| BLLN BillionToOne, Inc. compare | 9.02% |
| VCYT Veracyte, Inc. compare | 8.63% |
| QGEN QIAGEN N.V. compare | 6.99% |
| SHC Sotera Health Company compare | 5.28% |
| ICLR ICON PLC compare | 2.74% |
| RDNT RadNet, Inc. | −0.55% |
| ADPT Adaptive Biotechnologies Corporation compare | −12.0% |
| GRAL GRAIL, Inc. compare | −15.2% |
| Diagnostics & Research industry median | −6.05% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on RDNT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement